Ontology highlight
ABSTRACT:
SUBMITTER: Shim HH
PROVIDER: S-EPMC6207060 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
Shim Hang Hock HH Chan Pak Wo PW Chuah Sai Wei SW Schwender Brian J BJ Kong San Choon SC Ling Khoon Lin KL
JGH open : an open access journal of gastroenterology and hepatology 20180620 5
Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much-awaited out-of-class alternatives for patients who have failed or who are intolerant to anti-Tumor Necrosis Factor (TNF) therapy. However, questions remain as to how we may best use these novel therapeutic agents. We evaluate the evidence available from ...[more]